The Week Ahead In Biotech: J&J Earnings Kickstarts Pharma Earnings, More IPOs In The Pipeline, , on October 11, 2020 at 5:29 pm

Financial News
By High West Capital Partners
On October 11, 2020
In Financial News
Tags:

Biotech stocks advanced along with the broader market in the week ended Oct. 9, although the news flow was quite light.Antibody treatment for COVID-19 took the spotlight during the week, with both Eli Lilly And Co (NYSE: LLY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) requesting for emergency use authorizations. Regeneron was in the news even ahead of the EUA request, as President Trump was administered the company’s antibody cocktail after he was diagnosed COVID-19 positive.In a major breakthrough in the coronavirus vaccine space, Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) began rolling submission of the BLA for their jointly-developed mRNA vaccine – BNT16b2 in Europe.Pre-announcement season kickstarted, with most companies reporting above-consensus preliminary revenues for the quarter ended Sept. 30.A multi-billion-dollar deal was announced during the week, with Bristol-Myers Squibb Co. (NYSE: BMY) agreeing to buy Myokardia Inc. (NASDAQ: MYOK) for $13.1 billion.View more earnings on IBBThe week also witnessed 3 biotechs debuting on Wall Street following their IPOs, which raised a cumulative $390.04 million in gross proceeds.Here’re the key catalysts for the unfolding week:Conferences * United European Gastroenterology, or UEG, Week 2020: Oct. 11-13 * Cell & Gene Meeting on the Mesa 2020: Oct. 12-16 * Joint 49th Child Neurology Society Annual Meeting/16th International Child Neurology Congress: Oct. 12-23 * European Society for Immunodeficiencies, or ESID, 2020 Meeting: Oct. 14-17 * Related Link: Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates Clinical Readouts Bristol-Myers Squibb is scheduled to host a virtual investor event at 8 a.m. ET Monday to present results from the Phase 3 True North trial evaluating Zeposia in patients with moderate to severe ulcerative colitis. The data will subsequently be presented at the UEG Week.Rocket Pharmaceuticals Inc. (NASDAQ: RCKT) is scheduled to present at the ESID meeting an update on data from the Phase 1 portion of the Phase 1/2 clinical trial of RP-L201, lentiviral-mediated ex-vivo gene therapy, for leukocyte adhesion deficiency-I. The company will also present an e-poster consisting of preclinical study data on RP-L401 for infantile malignant osteopetrosis.Earnings * Johnson & Johnson (NYSE: JNJ) (Tuesday, before the market open) * Enzo Biochem Inc. (NYSE: ENZ) (Tuesday, after the close) * Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) (Thursday, before the market open) * Intuitive Surgical Inc. (NASDAQ: ISRG) (Thursday, after the close)IPOs Cambridge, Massachusetts-based Codiak BioSciences has filed with the SEC a preliminary prospectus to offer 5 million shares of its common stock at an estimated price range of $14-$16. The clinical-stage biopharma focused on pioneering the development of exosome-based therapeutics said it has applied for listing its shares on the Nasdaq under the ticker symbol CDAK.Praxis Precision Medicines Inc., also from Cambridge in Massachusetts, is planning a 7.4-million-share IPO at an estimated price range of $16-$18. The company, which translates genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, is expected to list its shares on the Nasdaq under the ticker symbol PRAX.Carlsbad, California-based Spinal Elements Holdings Inc., a medical device company developing comprehensive portfolio of systems, products and technologies for spine surgery procedures, said it has filed to offer 7.7 million shares in an IPO at an estimated price range of $13-$15. The company has applied for listing its shares on the Nasdaq under the ticker symbol SPEL.IPO Quiet Period Expiry * Metacrine Inc (NASDAQ: MTCR) * Dyne Therapeutics Inc (NASDAQ: DYN) * Athira Pharma Inc (NASDAQ: ATHA) * Outset Medical Inc (NASDAQ: OM)Related Link: FDA’s COVID-19 Vaccine Guidance Shows ‘Substantial’ Obligations For Developers: Analyst See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * The Daily Biotech Pulse: FDA Panel Review For Alkermes, Axovant Gets Rare Pediatric Disease Designation, 2 IPOs * The Daily Biotech Pulse: Gilead, Lilly COVID-19 Treatment Supply Agreements, CareDx’s Positive Preannouncement, Aziyo Biologics Debuts On Wall Street(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.,

The Week Ahead In Biotech: J&J Earnings Kickstarts Pharma Earnings, More IPOs In The PipelineBiotech stocks advanced along with the broader market in the week ended Oct. 9, although the news flow was quite light.Antibody treatment for COVID-19 took the spotlight during the week, with both Eli Lilly And Co (NYSE: LLY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) requesting for emergency use authorizations. Regeneron was in the news even ahead of the EUA request, as President Trump was administered the company’s antibody cocktail after he was diagnosed COVID-19 positive.In a major breakthrough in the coronavirus vaccine space, Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) began rolling submission of the BLA for their jointly-developed mRNA vaccine – BNT16b2 in Europe.Pre-announcement season kickstarted, with most companies reporting above-consensus preliminary revenues for the quarter ended Sept. 30.A multi-billion-dollar deal was announced during the week, with Bristol-Myers Squibb Co. (NYSE: BMY) agreeing to buy Myokardia Inc. (NASDAQ: MYOK) for $13.1 billion.View more earnings on IBBThe week also witnessed 3 biotechs debuting on Wall Street following their IPOs, which raised a cumulative $390.04 million in gross proceeds.Here’re the key catalysts for the unfolding week:Conferences * United European Gastroenterology, or UEG, Week 2020: Oct. 11-13 * Cell & Gene Meeting on the Mesa 2020: Oct. 12-16 * Joint 49th Child Neurology Society Annual Meeting/16th International Child Neurology Congress: Oct. 12-23 * European Society for Immunodeficiencies, or ESID, 2020 Meeting: Oct. 14-17 * Related Link: Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates Clinical Readouts Bristol-Myers Squibb is scheduled to host a virtual investor event at 8 a.m. ET Monday to present results from the Phase 3 True North trial evaluating Zeposia in patients with moderate to severe ulcerative colitis. The data will subsequently be presented at the UEG Week.Rocket Pharmaceuticals Inc. (NASDAQ: RCKT) is scheduled to present at the ESID meeting an update on data from the Phase 1 portion of the Phase 1/2 clinical trial of RP-L201, lentiviral-mediated ex-vivo gene therapy, for leukocyte adhesion deficiency-I. The company will also present an e-poster consisting of preclinical study data on RP-L401 for infantile malignant osteopetrosis.Earnings * Johnson & Johnson (NYSE: JNJ) (Tuesday, before the market open) * Enzo Biochem Inc. (NYSE: ENZ) (Tuesday, after the close) * Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) (Thursday, before the market open) * Intuitive Surgical Inc. (NASDAQ: ISRG) (Thursday, after the close)IPOs Cambridge, Massachusetts-based Codiak BioSciences has filed with the SEC a preliminary prospectus to offer 5 million shares of its common stock at an estimated price range of $14-$16. The clinical-stage biopharma focused on pioneering the development of exosome-based therapeutics said it has applied for listing its shares on the Nasdaq under the ticker symbol CDAK.Praxis Precision Medicines Inc., also from Cambridge in Massachusetts, is planning a 7.4-million-share IPO at an estimated price range of $16-$18. The company, which translates genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, is expected to list its shares on the Nasdaq under the ticker symbol PRAX.Carlsbad, California-based Spinal Elements Holdings Inc., a medical device company developing comprehensive portfolio of systems, products and technologies for spine surgery procedures, said it has filed to offer 7.7 million shares in an IPO at an estimated price range of $13-$15. The company has applied for listing its shares on the Nasdaq under the ticker symbol SPEL.IPO Quiet Period Expiry * Metacrine Inc (NASDAQ: MTCR) * Dyne Therapeutics Inc (NASDAQ: DYN) * Athira Pharma Inc (NASDAQ: ATHA) * Outset Medical Inc (NASDAQ: OM)Related Link: FDA’s COVID-19 Vaccine Guidance Shows ‘Substantial’ Obligations For Developers: Analyst See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * The Daily Biotech Pulse: FDA Panel Review For Alkermes, Axovant Gets Rare Pediatric Disease Designation, 2 IPOs * The Daily Biotech Pulse: Gilead, Lilly COVID-19 Treatment Supply Agreements, CareDx’s Positive Preannouncement, Aziyo Biologics Debuts On Wall Street(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

168 Robinson Road,
Capital Tower, Singapore 068912
+65 3105 1295

Taiwan

5th Floor, No. 1-8, Section 5, Zhongxiao East Road, Taipei

Hong Kong

R91, 3rd Floor,
Eton Tower, 8 Hysan Ave.
Causeway Bay, Hong Kong
+852 3002 4462

Australia

44 Martin Place, Sydney 2000 Australia
+02 8319 3232

Indonesia

Millennium Centennial Center, 38th Floor, Jl. Jend. Sudirman Kav. 25
Jakarta 12920, Indonesia

Market Coverage